Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.13%. Meanwhile, the Dow lost 1.33%, and the Nasdaq, a tech-heavy index, lost 0.13%.

The company's stock has dropped by 21.52% in the past month, falling short of the Medical sector's loss of 8.46% and the S&P 500's loss of 6.3%.

Market participants will be closely following the financial results of Viking Therapeutics, Inc. in its upcoming release. The company plans to announce its earnings on April 23, 2025. The company's upcoming EPS is projected at -$0.34, signifying a 30.77% drop compared to the same quarter of the previous year.

It is also important to note the recent changes to analyst estimates for Viking Therapeutics, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. As of now, Viking Therapeutics, Inc. holds a Zacks Rank of #4 (Sell).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 31% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research